Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer Academic Article uri icon

Overview

MeSH Major

  • Factor Xa Inhibitors
  • Neoplasms
  • Rivaroxaban
  • Venous Thromboembolism

abstract

  • In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).

publication date

  • February 21, 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1814630

PubMed ID

  • 30786186

Additional Document Info

start page

  • 720

end page

  • 728

volume

  • 380

number

  • 8